MELPHALAN PHARMEXON 50 mg Roumanie - roumain - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

melphalan pharmexon 50 mg

emcure pharma uk limited - marea britanie - melphalanum - pulb. si solv. pt. sol. inj./perf. - 50mg - agenti alchilanti analogi de nitrogen mustard

MELFALAN AMRING 50 mg Roumanie - roumain - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

melfalan amring 50 mg

drehm pharma gmbh - austria - melphalanum - pulb.+solv. pt. sol. inj./perf. - 50mg - agenti alchilanti analogi de nitrogen mustard

MELFALAN TILLOMED 50 mg Roumanie - roumain - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

melfalan tillomed 50 mg

tillomed pharma gmbh - germania - melphalanum - pulb. si solv. pt. sol. inj./perf. - 50mg - agenti alchilanti analogi de nitrogen mustard

Enhertu Union européenne - roumain - EMA (European Medicines Agency)

enhertu

daiichi sankyo europe gmbh - trastuzumab deruxtecan - sânii neoplasme - agenți antineoplazici - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

PAZOPANIB ADALVO 200 mg Roumanie - roumain - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pazopanib adalvo 200 mg

alvogen malta (out-licensing) ltd./amol ltd. - malta - pazopanib - compr. film. - 200mg - inhibitori de protein-kinaza

Gavreto Union européenne - roumain - EMA (European Medicines Agency)

gavreto

roche registration gmbh  - pralsetinib - carcinom, pulmonar non-celulă mică - agenți antineoplazici - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.

MELFALAN ZENTIVA 50 mg Roumanie - roumain - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

melfalan zentiva 50 mg

mias pharma limited - irlanda - melphalanum - pulb. si solv. pt. sol. inj./perf. - 50mg - agenti alchilanti analogi de nitrogen mustard

PAZOPANIB ZENTIVA 200 mg Roumanie - roumain - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pazopanib zentiva 200 mg

remedica ltd - cipru - pazopanibum - compr. film. - 200mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza

PAZOPANIB ZENTIVA 400 mg Roumanie - roumain - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pazopanib zentiva 400 mg

remedica ltd - cipru - pazopanibum - compr. film. - 400mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza

PYZYPI 200 mg Roumanie - roumain - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pyzypi 200 mg

remedica ltd - cipru - pazopanibum - compr. film. - 200mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza